Nachrichten und Videos - AVADEL PHARMACEUTICALS PLC ORD.

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23 rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com , for...

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Monday, March 11 at 3:20 p.m. ET. UBS Virtual CNS Day: Fireside chat on Monday, March 18 at 12:30 p.m. ET. A live webcast of these events, as well as an archived...

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™. Avadel is pleased with the jury’s decision ruling in favor of Avadel with respect to one of the contested patents. As it relates to the jury’s decision against Avadel regarding the additional...

-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200 patients initiated therapy -- -- Payer coverage now in place for greater than 80% of commercially covered lives for LUMRYZ through new listings including United Healthcare and Anthem -- -- FDA target action date of September 7, 2024, issued for the Supplemental New Drug Application...

DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023. Avadel plans to issue its Annual Report on Form 10-K for the year ended...

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Wednesday, February 14 at 2:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website,...

-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively -- -- Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUP TM and more than 1,000 patients initiating therapy through December 31 -- -- Signed Emisar (Optum Rx GPO) contract, all 3 PBM owned GPO contracts now finalized for 2024 -- -- Supplemental New Drug Application (sNDA) for LUMRYZ in the pediatric...

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 -- -- Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7 th -- -- Management to host a conference call today at 8:30 a.m. ET --...

DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 14 at 5:00 p.m. GMT / 12:00 p.m. ET. Piper Sandler 35 th Annual Healthcare Conference: Fireside chat on Wednesday, November 29 at 11:30 a.m....

DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. A live audio webcast of the call be accessed by visiting the investor relations...

– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with leading KOLs discussing evolution of the narcolepsy treatment landscape – DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new and encore data supporting the...

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Biotech CNS/Neuro Summit on Thursday, October 12 at 9:00 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com , for 90...

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 7 at 4:30 p.m. ET. H.C. Wainwright 25 th Annual Global Investment Conference: Fireside chat on Monday, September 11 at 10:00 a.m. ET. Cantor...

-- Successfully commenced U.S. commercial launch of LUMRYZ™ -- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 26,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with...

DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 9, 2023, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2023. A live audio webcast of the call be accessed by visiting the investor relations section of...

DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with...

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase an aggregate of 90,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with...

DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a Commercial Day presentation to provide an overview of its commercial strategy for recently launched LUMRYZ on Thursday, June 29, 2023 beginning at 8:00 a.m. ET. LUMRYZ was approved by the U.S. Food & Drug Administration (FDA) in May 2023 for the treatment of cataplexy or excessive...

DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of the American Academy of Sleep Medicine (AASM) Foundation’s 15 th Annual Young Investigators Research Forum (YIRF). This will be Avadel’s third year as lead sponsor of the YIRF program, which takes place March-June 2023, with virtual events and in-person events. Avadel has supported AASM...